ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Hanyang, Seoul, KOR:

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Active, not recruiting
Atopic Hand Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Tralokinumab

Phase 3

LEO Pharma
LEO Pharma

Seoul, South Korea and 69 other locations

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 52 other locations

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Active, not recruiting
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Seoul, Korea, Republic of and 91 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Seoul, South Korea and 540 other locations

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants w...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of and 45 other locations

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 95 other locations

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Biological: ADSTEM Inj.

Phase 2

EHL Bio

Seoul, Seoulteukbyeolsi, Korea, Republic of and 5 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.

Active, not recruiting
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Seoul, Korea, Republic of and 46 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Seoul, South Korea and 556 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Seoul, Korea, Republic of and 194 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems